Brian Sauer
Concepts (394)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 42 | 2024 | 1185 | 5.710 |
Why?
| | Antirheumatic Agents | 24 | 2024 | 309 | 5.240 |
Why?
| | Veterans | 32 | 2023 | 1650 | 3.610 |
Why?
| | Spondylitis, Ankylosing | 5 | 2020 | 43 | 2.320 |
Why?
| | Hyperkalemia | 3 | 2023 | 35 | 2.160 |
Why?
| | Veterans Health | 8 | 2023 | 188 | 2.050 |
Why?
| | United States Department of Veterans Affairs | 12 | 2021 | 777 | 1.810 |
Why?
| | Methotrexate | 10 | 2021 | 234 | 1.750 |
Why?
| | Spondylarthritis | 3 | 2020 | 50 | 1.220 |
Why?
| | Natural Language Processing | 4 | 2023 | 103 | 1.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2019 | 266 | 1.140 |
Why?
| | Rheumatology | 2 | 2020 | 136 | 1.130 |
Why?
| | Biological Products | 6 | 2021 | 258 | 1.110 |
Why?
| | Registries | 18 | 2024 | 2400 | 1.090 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2024 | 1224 | 1.060 |
Why?
| | Medication Adherence | 4 | 2019 | 535 | 1.000 |
Why?
| | Drug Substitution | 3 | 2021 | 62 | 0.890 |
Why?
| | Psoriasis | 2 | 2015 | 110 | 0.810 |
Why?
| | Arthritis, Psoriatic | 3 | 2019 | 15 | 0.790 |
Why?
| | Lymphoma, Follicular | 2 | 2021 | 57 | 0.780 |
Why?
| | Sulfasalazine | 3 | 2019 | 22 | 0.760 |
Why?
| | Aged | 46 | 2024 | 26432 | 0.760 |
Why?
| | Misoprostol | 1 | 2022 | 15 | 0.720 |
Why?
| | Hydroxychloroquine | 3 | 2019 | 65 | 0.720 |
Why?
| | HLA-B27 Antigen | 3 | 2019 | 16 | 0.710 |
Why?
| | Lung Diseases, Interstitial | 6 | 2024 | 677 | 0.690 |
Why?
| | Humans | 97 | 2024 | 146342 | 0.680 |
Why?
| | Middle Aged | 47 | 2024 | 36619 | 0.650 |
Why?
| | Databases, Factual | 7 | 2018 | 1493 | 0.650 |
Why?
| | United States | 31 | 2023 | 16136 | 0.640 |
Why?
| | Cohort Studies | 16 | 2024 | 6077 | 0.630 |
Why?
| | Rituximab | 2 | 2021 | 208 | 0.630 |
Why?
| | Electronic Health Records | 6 | 2023 | 1210 | 0.630 |
Why?
| | Infliximab | 3 | 2016 | 107 | 0.620 |
Why?
| | Pharmaceutical Services | 2 | 2019 | 76 | 0.600 |
Why?
| | Insurance Claim Review | 2 | 2017 | 87 | 0.600 |
Why?
| | Practice Patterns, Physicians' | 5 | 2019 | 1408 | 0.600 |
Why?
| | Buprenorphine | 1 | 2023 | 197 | 0.580 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 344 | 0.580 |
Why?
| | Analgesics, Opioid | 5 | 2020 | 1221 | 0.580 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 54 | 0.570 |
Why?
| | Algorithms | 5 | 2020 | 1849 | 0.570 |
Why?
| | Arthritis | 2 | 2021 | 97 | 0.570 |
Why?
| | Datasets as Topic | 1 | 2019 | 120 | 0.560 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2019 | 61 | 0.550 |
Why?
| | Treatment Outcome | 19 | 2024 | 11821 | 0.550 |
Why?
| | Severity of Illness Index | 12 | 2023 | 2921 | 0.540 |
Why?
| | Etanercept | 2 | 2016 | 60 | 0.540 |
Why?
| | Adalimumab | 2 | 2016 | 53 | 0.530 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 200 | 0.530 |
Why?
| | Male | 54 | 2024 | 73396 | 0.530 |
Why?
| | Iron | 2 | 2021 | 359 | 0.510 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 589 | 0.490 |
Why?
| | Chronic Pain | 3 | 2022 | 304 | 0.470 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2021 | 640 | 0.470 |
Why?
| | Computer Simulation | 4 | 2020 | 1014 | 0.460 |
Why?
| | Delivery of Health Care | 2 | 2022 | 947 | 0.450 |
Why?
| | Drug Monitoring | 4 | 2012 | 399 | 0.450 |
Why?
| | Female | 49 | 2024 | 79499 | 0.450 |
Why?
| | Terminology as Topic | 1 | 2017 | 253 | 0.440 |
Why?
| | Healthcare Common Procedure Coding System | 1 | 2014 | 1 | 0.430 |
Why?
| | Cross-Over Studies | 1 | 2017 | 615 | 0.430 |
Why?
| | Diabetes Mellitus | 3 | 2024 | 1101 | 0.430 |
Why?
| | Polymers | 3 | 2023 | 488 | 0.420 |
Why?
| | Risk Factors | 23 | 2024 | 10921 | 0.420 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 634 | 0.420 |
Why?
| | Research Design | 3 | 2020 | 1143 | 0.420 |
Why?
| | Insurance, Pharmaceutical Services | 2 | 2011 | 23 | 0.410 |
Why?
| | Adipokines | 3 | 2022 | 56 | 0.410 |
Why?
| | Cytokines | 5 | 2024 | 2081 | 0.400 |
Why?
| | Narcotics | 1 | 2013 | 57 | 0.390 |
Why?
| | Models, Statistical | 2 | 2017 | 669 | 0.380 |
Why?
| | Hospitalization | 5 | 2021 | 2475 | 0.360 |
Why?
| | Utah | 7 | 2013 | 82 | 0.360 |
Why?
| | Ambulatory Care | 2 | 2014 | 628 | 0.360 |
Why?
| | Potassium | 2 | 2023 | 151 | 0.360 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 171 | 0.360 |
Why?
| | Pharmaceutical Preparations | 3 | 2022 | 172 | 0.350 |
Why?
| | Remission Induction | 3 | 2022 | 308 | 0.350 |
Why?
| | Drug Prescriptions | 2 | 2013 | 314 | 0.350 |
Why?
| | Medicine | 1 | 2013 | 127 | 0.350 |
Why?
| | Emergency Service, Hospital | 3 | 2023 | 2363 | 0.340 |
Why?
| | Time Factors | 11 | 2021 | 7109 | 0.330 |
Why?
| | Drug Overdose | 2 | 2012 | 377 | 0.330 |
Why?
| | Carpal Bones | 2 | 2021 | 18 | 0.330 |
Why?
| | Proportional Hazards Models | 8 | 2022 | 1331 | 0.330 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2015 | 352 | 0.310 |
Why?
| | Decision Support Systems, Clinical | 2 | 2012 | 279 | 0.310 |
Why?
| | Cardiovascular Diseases | 8 | 2023 | 2219 | 0.310 |
Why?
| | Disease Progression | 2 | 2018 | 2867 | 0.310 |
Why?
| | Potentially Inappropriate Medication List | 2 | 2020 | 17 | 0.310 |
Why?
| | Health Services Accessibility | 2 | 2019 | 1107 | 0.310 |
Why?
| | Adiponectin | 4 | 2024 | 243 | 0.300 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1591 | 0.300 |
Why?
| | Quality Indicators, Health Care | 1 | 2012 | 343 | 0.290 |
Why?
| | C-Reactive Protein | 4 | 2021 | 429 | 0.290 |
Why?
| | Retrospective Studies | 18 | 2023 | 17438 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 970 | 0.270 |
Why?
| | Risk Assessment | 10 | 2021 | 3712 | 0.270 |
Why?
| | Body Mass Index | 6 | 2018 | 2458 | 0.260 |
Why?
| | Aged, 80 and over | 13 | 2021 | 8391 | 0.260 |
Why?
| | Pneumonia, Bacterial | 2 | 2020 | 114 | 0.260 |
Why?
| | Incidence | 9 | 2024 | 2936 | 0.260 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1512 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1408 | 0.250 |
Why?
| | Prospective Studies | 9 | 2024 | 8123 | 0.250 |
Why?
| | ROC Curve | 3 | 2019 | 617 | 0.250 |
Why?
| | International Classification of Diseases | 4 | 2023 | 142 | 0.250 |
Why?
| | Arthrodesis | 3 | 2021 | 38 | 0.240 |
Why?
| | Managed Care Programs | 1 | 2007 | 137 | 0.230 |
Why?
| | Multimorbidity | 2 | 2023 | 65 | 0.230 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2113 | 0.230 |
Why?
| | Drug Utilization | 2 | 2018 | 171 | 0.220 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1036 | 0.220 |
Why?
| | Embryo, Nonmammalian | 2 | 2005 | 171 | 0.210 |
Why?
| | Propensity Score | 3 | 2020 | 376 | 0.210 |
Why?
| | Patient Admission | 1 | 2007 | 216 | 0.210 |
Why?
| | Gene Targeting | 1 | 2004 | 76 | 0.210 |
Why?
| | Data Mining | 3 | 2023 | 113 | 0.210 |
Why?
| | Alarmins | 1 | 2024 | 27 | 0.210 |
Why?
| | Interleukin-33 | 1 | 2024 | 45 | 0.210 |
Why?
| | Regression Analysis | 3 | 2018 | 999 | 0.200 |
Why?
| | Adult | 16 | 2022 | 41087 | 0.200 |
Why?
| | Embryo, Mammalian | 1 | 2004 | 230 | 0.200 |
Why?
| | Wrist | 2 | 2021 | 60 | 0.190 |
Why?
| | Poisson Distribution | 2 | 2017 | 77 | 0.190 |
Why?
| | Wrist Joint | 2 | 2021 | 72 | 0.190 |
Why?
| | Polystyrenes | 1 | 2023 | 38 | 0.190 |
Why?
| | Neurology | 1 | 2024 | 107 | 0.180 |
Why?
| | Diclofenac | 1 | 2022 | 14 | 0.180 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5439 | 0.180 |
Why?
| | Chemokines | 2 | 2021 | 217 | 0.180 |
Why?
| | Weight Loss | 2 | 2018 | 858 | 0.180 |
Why?
| | Neoplasms | 5 | 2023 | 2954 | 0.180 |
Why?
| | Blood Sedimentation | 2 | 2019 | 38 | 0.180 |
Why?
| | Comorbidity | 4 | 2023 | 1665 | 0.180 |
Why?
| | Research Report | 1 | 2022 | 89 | 0.180 |
Why?
| | Stroke | 2 | 2021 | 1287 | 0.180 |
Why?
| | Confidence Intervals | 2 | 2016 | 329 | 0.170 |
Why?
| | Rheumatic Diseases | 1 | 2023 | 101 | 0.170 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1031 | 0.170 |
Why?
| | Genetic Testing | 1 | 2004 | 492 | 0.170 |
Why?
| | Linear Models | 3 | 2018 | 857 | 0.170 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1543 | 0.160 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2021 | 20 | 0.160 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 256 | 0.160 |
Why?
| | Education, Medical | 1 | 2024 | 274 | 0.160 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 41 | 0.160 |
Why?
| | Prescription Drugs | 2 | 2012 | 110 | 0.160 |
Why?
| | Communication | 2 | 2024 | 980 | 0.150 |
Why?
| | Cyclophosphamide | 2 | 2021 | 275 | 0.150 |
Why?
| | Stem Cells | 1 | 2004 | 613 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2021 | 100 | 0.150 |
Why?
| | Arthritis, Infectious | 1 | 2021 | 77 | 0.150 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2020 | 26 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2020 | 313 | 0.150 |
Why?
| | SEER Program | 1 | 2020 | 233 | 0.150 |
Why?
| | Transferrin | 1 | 2019 | 48 | 0.150 |
Why?
| | Ferritins | 1 | 2019 | 69 | 0.140 |
Why?
| | Ranolazine | 1 | 2018 | 23 | 0.140 |
Why?
| | Inappropriate Prescribing | 1 | 2019 | 68 | 0.140 |
Why?
| | Bipolar Disorder | 1 | 2021 | 285 | 0.140 |
Why?
| | Angina, Stable | 1 | 2018 | 18 | 0.140 |
Why?
| | Area Under Curve | 1 | 2019 | 335 | 0.140 |
Why?
| | Geriatrics | 1 | 2019 | 96 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2022 | 751 | 0.130 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2021 | 193 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 195 | 0.130 |
Why?
| | Professional Practice Location | 1 | 2017 | 26 | 0.130 |
Why?
| | Rheumatologists | 1 | 2017 | 15 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2020 | 253 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.130 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2019 | 129 | 0.130 |
Why?
| | Sacroiliitis | 1 | 2017 | 7 | 0.130 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2018 | 89 | 0.130 |
Why?
| | Osteoarthritis | 1 | 2020 | 206 | 0.130 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 165 | 0.130 |
Why?
| | Heart Failure | 2 | 2021 | 2329 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2021 | 362 | 0.130 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 48 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 2018 | 103 | 0.130 |
Why?
| | Longitudinal Studies | 4 | 2023 | 3017 | 0.130 |
Why?
| | Bias | 3 | 2013 | 197 | 0.130 |
Why?
| | Disability Evaluation | 1 | 2018 | 297 | 0.120 |
Why?
| | Data Accuracy | 1 | 2017 | 64 | 0.120 |
Why?
| | Population Surveillance | 2 | 2012 | 481 | 0.120 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2018 | 253 | 0.120 |
Why?
| | Risk Management | 2 | 2007 | 81 | 0.120 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 693 | 0.120 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 80 | 0.120 |
Why?
| | Leptin | 3 | 2022 | 248 | 0.120 |
Why?
| | Recovery of Function | 1 | 2021 | 725 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2007 | 81 | 0.120 |
Why?
| | Travel | 1 | 2017 | 134 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 388 | 0.120 |
Why?
| | Feasibility Studies | 2 | 2020 | 1135 | 0.120 |
Why?
| | Pain | 1 | 2022 | 790 | 0.120 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 141 | 0.120 |
Why?
| | Hypertension | 2 | 2018 | 1272 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2018 | 474 | 0.120 |
Why?
| | Precision Medicine | 1 | 2020 | 462 | 0.120 |
Why?
| | Neoplasm Staging | 1 | 2020 | 1488 | 0.120 |
Why?
| | Prognosis | 3 | 2020 | 4351 | 0.120 |
Why?
| | Fees, Pharmaceutical | 1 | 2015 | 8 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 136 | 0.110 |
Why?
| | Drug Administration Routes | 1 | 2015 | 41 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 133 | 0.110 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2021 | 385 | 0.110 |
Why?
| | Anti-Infective Agents | 1 | 2018 | 234 | 0.110 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 250 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5899 | 0.110 |
Why?
| | Cyclosporine | 1 | 2016 | 256 | 0.110 |
Why?
| | Cause of Death | 4 | 2023 | 456 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2017 | 229 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2020 | 1051 | 0.110 |
Why?
| | Logistic Models | 2 | 2018 | 2126 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 423 | 0.110 |
Why?
| | Recombination, Genetic | 3 | 2005 | 202 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2017 | 508 | 0.110 |
Why?
| | Cross Infection | 1 | 2017 | 258 | 0.100 |
Why?
| | Obesity | 2 | 2018 | 3131 | 0.100 |
Why?
| | Suicide | 1 | 2021 | 647 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 790 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2018 | 536 | 0.100 |
Why?
| | Health Expenditures | 1 | 2015 | 198 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2018 | 594 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 432 | 0.100 |
Why?
| | Prednisone | 3 | 2021 | 229 | 0.100 |
Why?
| | Quality Improvement | 1 | 2022 | 1354 | 0.100 |
Why?
| | Causality | 1 | 2013 | 128 | 0.090 |
Why?
| | Integrases | 3 | 2005 | 117 | 0.090 |
Why?
| | Adiposity | 1 | 2017 | 533 | 0.090 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2012 | 38 | 0.090 |
Why?
| | Telemedicine | 1 | 2022 | 966 | 0.090 |
Why?
| | Education, Medical, Continuing | 1 | 2013 | 130 | 0.090 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1327 | 0.090 |
Why?
| | Root Cause Analysis | 1 | 2012 | 11 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 635 | 0.090 |
Why?
| | Mortality | 1 | 2015 | 375 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 183 | 0.090 |
Why?
| | Occupational Injuries | 1 | 2012 | 49 | 0.090 |
Why?
| | HIV Infections | 2 | 2018 | 3215 | 0.090 |
Why?
| | Florida | 1 | 2012 | 117 | 0.090 |
Why?
| | Prescription Drug Misuse | 1 | 2012 | 58 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 787 | 0.090 |
Why?
| | HIV-1 | 1 | 2018 | 913 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2022 | 2675 | 0.080 |
Why?
| | Outpatients | 1 | 2014 | 440 | 0.080 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 62 | 0.080 |
Why?
| | Risk | 1 | 2013 | 920 | 0.080 |
Why?
| | Health Personnel | 1 | 2017 | 754 | 0.080 |
Why?
| | Narration | 1 | 2012 | 82 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2219 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 280 | 0.080 |
Why?
| | Adolescent | 5 | 2015 | 22557 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3416 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2022 | 0.080 |
Why?
| | Substance-Related Disorders | 2 | 2023 | 1100 | 0.070 |
Why?
| | Blood Pressure | 2 | 2018 | 1765 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1942 | 0.070 |
Why?
| | Young Adult | 3 | 2015 | 14330 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2008 | 74 | 0.070 |
Why?
| | Sex Factors | 3 | 2021 | 2107 | 0.070 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2008 | 92 | 0.070 |
Why?
| | Hospital Records | 1 | 2007 | 10 | 0.070 |
Why?
| | Financing, Personal | 1 | 2007 | 26 | 0.070 |
Why?
| | Catheter-Related Infections | 1 | 2008 | 101 | 0.060 |
Why?
| | Cost Sharing | 1 | 2007 | 23 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2011 | 519 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2007 | 96 | 0.060 |
Why?
| | Biomarkers | 3 | 2024 | 4340 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2005 | 371 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2013 | 881 | 0.060 |
Why?
| | Insulin-Like Growth Factor I | 2 | 1999 | 320 | 0.060 |
Why?
| | Viral Proteins | 2 | 1999 | 351 | 0.060 |
Why?
| | Machine Learning | 2 | 2022 | 594 | 0.060 |
Why?
| | Primary Health Care | 2 | 2013 | 1776 | 0.060 |
Why?
| | Drug Interactions | 1 | 2007 | 405 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2008 | 561 | 0.050 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 178 | 0.050 |
Why?
| | Health Services Research | 1 | 2007 | 390 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2004 | 82 | 0.050 |
Why?
| | Data Collection | 1 | 2007 | 650 | 0.050 |
Why?
| | Inpatients | 2 | 2024 | 540 | 0.050 |
Why?
| | Chronic Disease | 2 | 2022 | 1827 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2024 | 121 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2008 | 389 | 0.050 |
Why?
| | Myocardial Infarction | 1 | 2011 | 1215 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1307 | 0.050 |
Why?
| | Mental Disorders | 1 | 2012 | 1148 | 0.050 |
Why?
| | Vital Capacity | 1 | 2023 | 293 | 0.050 |
Why?
| | Health Status | 2 | 2018 | 827 | 0.050 |
Why?
| | Odds Ratio | 2 | 2018 | 1077 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 26 | 0.050 |
Why?
| | Telomere Shortening | 1 | 2022 | 20 | 0.050 |
Why?
| | Antimanic Agents | 1 | 2021 | 14 | 0.040 |
Why?
| | Lithium | 1 | 2021 | 38 | 0.040 |
Why?
| | Valproic Acid | 1 | 2021 | 45 | 0.040 |
Why?
| | Medicare | 1 | 2007 | 920 | 0.040 |
Why?
| | Medication Therapy Management | 1 | 2022 | 73 | 0.040 |
Why?
| | Length of Stay | 1 | 2007 | 1358 | 0.040 |
Why?
| | Chlorambucil | 1 | 2021 | 11 | 0.040 |
Why?
| | Vidarabine | 1 | 2021 | 32 | 0.040 |
Why?
| | Bendamustine Hydrochloride | 1 | 2021 | 18 | 0.040 |
Why?
| | Bortezomib | 1 | 2021 | 54 | 0.040 |
Why?
| | Pulmonologists | 1 | 2020 | 14 | 0.040 |
Why?
| | Patient Discharge | 2 | 2023 | 997 | 0.040 |
Why?
| | Zebrafish | 1 | 2005 | 536 | 0.040 |
Why?
| | Data Display | 1 | 2020 | 20 | 0.040 |
Why?
| | Vincristine | 1 | 2021 | 148 | 0.040 |
Why?
| | Quality Control | 1 | 2020 | 163 | 0.040 |
Why?
| | Computed Tomography Angiography | 1 | 2021 | 151 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2022 | 293 | 0.040 |
Why?
| | Embryonic and Fetal Development | 1 | 1999 | 90 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2020 | 168 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 301 | 0.040 |
Why?
| | Piperidines | 1 | 2021 | 225 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2021 | 249 | 0.040 |
Why?
| | Pharmacists | 1 | 2022 | 260 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2021 | 446 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3926 | 0.040 |
Why?
| | Telomere | 1 | 2022 | 300 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 368 | 0.030 |
Why?
| | Doxorubicin | 1 | 2021 | 416 | 0.030 |
Why?
| | Adenine | 1 | 2021 | 339 | 0.030 |
Why?
| | Gene Dosage | 1 | 1998 | 146 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 706 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 640 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 2017 | 17 | 0.030 |
Why?
| | Infant Mortality | 1 | 1998 | 127 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 1999 | 902 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1133 | 0.030 |
Why?
| | HIV Integrase | 1 | 2018 | 74 | 0.030 |
Why?
| | Reoperation | 1 | 2020 | 645 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 257 | 0.030 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2018 | 165 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2017 | 278 | 0.030 |
Why?
| | Isoxazoles | 1 | 2016 | 57 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2017 | 270 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 100 | 0.030 |
Why?
| | Body Weight | 2 | 2016 | 968 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 908 | 0.030 |
Why?
| | Rheumatoid Factor | 1 | 2016 | 177 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 526 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1378 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 179 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1298 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 276 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 251 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 246 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6073 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3347 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2018 | 702 | 0.020 |
Why?
| | Life Style | 1 | 2016 | 496 | 0.020 |
Why?
| | Workers' Compensation | 1 | 2012 | 28 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2786 | 0.020 |
Why?
| | Coroners and Medical Examiners | 1 | 2011 | 8 | 0.020 |
Why?
| | Sampling Studies | 1 | 2011 | 97 | 0.020 |
Why?
| | Death Certificates | 1 | 2011 | 32 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2919 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1998 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2991 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1486 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 972 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 944 | 0.020 |
Why?
| | Medical Assistance | 1 | 2007 | 14 | 0.020 |
Why?
| | Models, Econometric | 1 | 2007 | 35 | 0.020 |
Why?
| | Psychoses, Substance-Induced | 1 | 2007 | 16 | 0.020 |
Why?
| | Deductibles and Coinsurance | 1 | 2007 | 13 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 731 | 0.020 |
Why?
| | Eligibility Determination | 1 | 2007 | 73 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3200 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2007 | 217 | 0.020 |
Why?
| | Child | 1 | 2007 | 22693 | 0.020 |
Why?
| | Delirium | 1 | 2007 | 107 | 0.010 |
Why?
| | Insurance Coverage | 1 | 2007 | 248 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 2005 | 73 | 0.010 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 190 | 0.010 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2005 | 76 | 0.010 |
Why?
| | Mosaicism | 1 | 2005 | 67 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2005 | 275 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 248 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1998 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 1999 | 2134 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3647 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2005 | 663 | 0.010 |
Why?
| | Hemorrhage | 1 | 2007 | 825 | 0.010 |
Why?
| | Liver | 2 | 1999 | 1864 | 0.010 |
Why?
| | Growth Disorders | 1 | 1998 | 89 | 0.010 |
Why?
| | Animals | 3 | 2005 | 38107 | 0.010 |
Why?
| | Mice | 2 | 1999 | 18297 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1998 | 2791 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1998 | 6460 | 0.000 |
Why?
|
|
Sauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|